Mr. Russell has been chairman of the board since May 2018, and a director since August 2014. He is also a member of Mallinckrodt’s Portfolio Committee and its Audit Committee.
He has served as the non-executive chairman of Revance Therapeutics, Inc. since March 2014. Mr. Russell has also served as a director of Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc.) since December 2014 and as a director of TherapeuticsMD, Inc. since March 2015.
Mr. Russell served as a director of Questcor Pharmaceuticals, Inc. from June 2013 until Questcor was acquired by Mallinckrodt in August 2014. He served as chief executive officer of Shire Plc from 2008 until his retirement in April 2013 and was a member of its board of directors from 1999 to 2013. From 1999 to 2008, Mr. Russell served as chief financial officer of Shire. Prior to joining Shire, he served at ICI, Zeneca and AstraZeneca, most recently as vice president of corporate finance at AstraZeneca. He was a director of InterMune, Inc. from 2011 to 2014.
Mr. Russell is a chartered accountant. He holds an honorary Doctor of Business Administration from Coventry University, U.K.